Navigation Links
Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
Date:8/30/2007

- Findings Published in Blood -

SAN DIEGO, Aug. 30 /PRNewswire/ -- Novocell Inc., a stem cell engineering company, today announced research findings that for the first time identify two prominent cancer cell signaling pathways as essential for the efficient proliferation and self-renewal of human embryonic stem cells (hESCs). The findings were prepublished online August 29, 2007 in Blood First Edition Paper titled "Self-Renewal of Human Embryonic Stem Cells Requires Insulin-like Growth Factor-1 Receptor and ERBB2 Receptor Signaling."

Researchers studying the self-renewal of hESCs discovered a link with insulin-like growth factor-1 (IGF-1R), and ERBB2/3. Both pathways are highly implicated in cancer and the target of numerous oncology therapeutics. EBRR2 is often overexpressed in breast cancer and other malignancies and is the target of the monoclonal antibody Herceptin. Researchers from Novocell, Invitrogen and the University of Washington collaborated on the published study.

"These new findings indicate for the first time that the major signaling pathways driving the self-renewal of human embryonic stem cells are also key pathways that signal inappropriately in a number of different cancers," said Allan Robins, Ph.D., senior author and Vice President and Chief Technical Officer of Novocell. "Such a linkage provides an avenue for Novocell to potentially identify new targets for oncology therapeutics using human embryonic stem cells."

"The implication that key cancer pathways are associated with human stem cell proliferation and self-renewal is yet another exciting outgrowth from the extensive stem cell research at Novocell that includes our defined media STEMPRO(R) hESC SFM licensed exclusively to Invitrogen and our cell therapy for diabetes," said Alan Lewis, Ph.D., President and CEO of Novocell.

About Novocell

Novocell Inc. is a stem cell engineering company with research operations in San Diego, CA, and Athens, GA, dedicated to creating, delivering, and commercializing cell and drug therapies for diabetes and other chronic diseases. Novocell is the first company to efficiently engineer human embryonic stem cells into definitive endoderm, the gatekeeper cells that differentiate into many other cells, tissues and organs. Novocell has three primary technologies: stem cell engineering, cell encapsulation, and drug discovery. The company was founded in 1999, merged with CyThera and BresaGen in 2004 and completed a $25M Series C financing in July 2007. For more information, visit http://www.novocell.com.


'/>"/>
SOURCE Novocell Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... IPSWICH, Mass. , Feb. 17, 2017 /PRNewswire/ ... a small tumor had a mutation-conferring resistance to ... treatment. Recently, genomics research has focused on finding ... — or even from circulating tumor DNA in ... identify new oncology therapeutics. Unfortunately, however, ...
(Date:2/16/2017)... ... February 16, 2017 , ... EIT Digital has launched work ... agricultural industry. Pilot studies are about to get under way for the framework, which ... 5G innovations. The concept is expected to be transferred eventually to other industries that ...
(Date:2/16/2017)... and GREENWICH, Conn. , ... investment firm focused on venture growth investments in ... of Josh Richardson , M.D. to Managing ... in biotechnology companies.  He is a board observer ... roles in Longitude,s investments in Aimmune Therapeutics, Akebia ...
(Date:2/16/2017)... Research and Markets has announced the addition ... to their offering. ... The study scope includes ... chassis organisms, synthetic cells, production systems), enabling technologies (DNA ... specialty media) and enabled technologies (biofuels, chemicals, pharmaceuticals, agriculture) ...
Breaking Biology Technology:
(Date:2/13/2017)...  RSA Conference -- RSA, a Dell Technologies business, ... enhance fraud detection and investigation across digital environments ... & Risk Intelligence Suite. The new platform is ... from internal and external sources as well as ... from targeted cybercrime attacks. "Fraudsters are ...
(Date:2/8/2017)... About Voice Recognition Biometrics Voice recognition biometrics ... a stored voiceprint template. Acoustic features of an ... are compared to distinguish between individual voices. Voice ... PCs already have a microphone and can authenticate ... are most likely to be deployed in telephone-based ...
(Date:2/8/2017)... Feb. 7, 2017 Report Highlights ... 2021 from $8.3 billion in 2016 at a compound ... 2021. Report Includes - An overview of the ... trends, with data from 2015 and 2016, and projections ... Segmentation of the market on the basis of product ...
Breaking Biology News(10 mins):